Vesalius Biocapital leads €15 million Series C round of HepaRegeniX
Tübingen/ Berlin — YPOG provided comprehensive legal advice to the lead investor Vesalius Biocapital IV in the € 15 million Series C financing round of HepaRegeniX GmbH. Existing investors such as Novo Holdings, Boehringer Ingelheim Venture Fund and High-Tech Gründerfonds also participated in the investment.
HepaRegeniX GmbH is a company in the field of clinical development of novel therapies for the treatment of acute and chronic liver diseases. Since its launch in 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel molecular target Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4). HRX-215 is a small molecule inhibitor of mitogen-activated protein (MAP) kinase kinase 4 (MKK4). This substance has the potential to significantly support liver regeneration in patients with liver metastases or primary liver tumors.
The new funding will support the Phase Ib/IIa clinical trial, which will focus on improving liver healing and preventing liver failure.
Advisor to HepaRegeniX: YPOG
Dr. Martin Schaper (Lead, Transactions), Partner, Berlin, Dr. Lutz Schreiber (IP/IT/Data Protection), Partner, Hamburg, Benjamin Müller (Transactions), Associate, Berlin, Matthias Treude (IP/IT/Data Protection), Associate, Hamburg, Cyra Dittberner (Transactions), Associate, Berlin
About Vesalius Biocapital IV
Vesalius Biocapital is an established European life sciences venture capital investor with a long track record of consistent returns, investing in the best/first-class European biopharma and healthtech companies.
The company invests in attractive companies at an advanced stage of development in the fields of drug development, medical technology and diagnostics as well as eHealth/mHealth, primarily in Europe. The portfolio companies address unmet medical and market needs and operate on the basis of strong intellectual property protection.
About YPOG
YPOG is a law firm specializing in tax and commercial law, active in the core areas of funds, tax, banking + finance and transactions. The YPOG team advises a wide variety of clients. These include emerging technology companies and family-run medium-sized enterprises as well as corporations and private equity/venture capital funds. YPOG is one of the leading addresses for venture capital, private equity and fund structuring in Germany. The firm and its partners are ranked nationally and internationally by JUVE, Best Lawyers, Legal 500, Focus, Chambers and Partners and Leaders League. Today, YPOG employs more than 120 experienced lawyers, tax consultants, tax specialists and a notary in three offices in Berlin, Hamburg and Cologne. http://www.ypog.law